.Johnson & Johnson's deprioritization of its own infectious disease pipe has professed another victim in the form of its own dengue infection vaccination mosnodenvir.Mosnodenvir is designed to block communications in between pair of dengue infection proteins. The vaccine made it through J&J's selection in 2015 to combine its own infectious health condition and vaccine functions, which found the likes of a late-stage respiratory system syncytial infection plan fell from the Significant Pharma's pipeline as well as an E. coli injection sold off to Sanofi.Mosnodenvir has actually possessed a bumpy ride in the clinic, along with J&J terminating one trial as a result of the impact of COVID-19 on registration as well as pausing recruitment in another research study in 2022. Yet the devotion to mosnodenvir seemed to pay in Oct 2023, when the injection was actually revealed to cause a dose-dependent antiviral impact on the detectability and onset of dengue virus serotype 3 in a stage 2 test.
That information reduce doesn't appear to have actually been enough to save mosnodenvir for long, with the Big Pharma announcing this morning that it is actually discontinuing a follow-up phase 2 field study. The choice is related to a "tactical reprioritization of the company's infectious conditions R&D portfolio," included J&J, which stressed that no safety and security concerns had actually been identified." Johnson & Johnson are going to continue to assist the fight versus dengue through discussing research study results along with the medical community in the future," the pharma stated in the launch.J&J had been acquiring dengue for over a many years, featuring releasing a Satellite Facility for Global Health Discovery at the Duke-NUS Medical College in Singapore in 2022. The center has been actually paid attention to accelerating early-stage exploration analysis to "resolve the growing challenge of flaviviruses" including dengue and also Zika.